Navigation Links
OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
Date:9/6/2011

rsen in first-line treatment of advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase II clinical development; CSP-9222 and OGX-225 are currently in pre-clinical development.

OncoGenex' Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial initiation and completion dates, patient enrollment targets, proposed amendments to our ongoing clinical trial design and the timing and possibility for approval by the FDA thereof, the timing and costs of our product development activities and the potential benefits of our product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk of delays in our expected clinical trials and the uncertainties regarding patient enrollment rates, the risk that the FDA does not approve our proposed amendment to the Saturn trial design in a timely fashion or at all, the risk that our product candidates do not obtain the requisite regulatory approvals to commercialize, the risk that new developments in the rapidly evolving prostate cancer therapy landscape require additional changes in our clinical trial design or limit the potential benefits of our product and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
2. OncoGenex Reports Third Quarter Financial Results
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
7. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. OncoGenex Reports Second Quarter Financial Results
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... A new report, commissioned by BioCrossroads and ... in-depth look at Indiana,s capital ... two different time frames: 1993 to 2002 and 2003 ... opportunities for investment growth.  The Life Science Innovation ... gains in innovation dollars as well as an increase ...
(Date:10/27/2014)... The new research report, “Gas ... Medium), Sub-type (Primary & Secondary), and End-User (Transmission ... & Power Generation) - Trends and Forecasts to ... analysis and forecasting of the market size. , ... 52 Figures spread through 146 Pages and in-depth ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 New ... SoundConnect , an industry leading unified communication ... partners and agents to deliver cloud-based audio and ... growth opportunities. , With SoundConnect’s Q4 incentive ... twenty-five video and/or web conferencing licenses sold, now ...
(Date:10/27/2014)... Investor-Edge has initiated coverage on ... NBIX ), Insmed Inc. (NASDAQ: INSM ), ... Corporation (NASDAQ: DYAX ), and Oncothyreon Inc. ... be accessed at: http://investor-edge.com/register . On ... 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced ...
Breaking Biology Technology:New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4SoundConnect Unveils Q4 Partner Incentives 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... Over the past couple of decades, atomic force microscopy ... surfaces at astonishing resolutionsfractions of a nanometer in some ... below the surface? Researchers at the National Institute of ... right circumstances, surface science instruments such as the AFM ...
... ... Zeiss, a leading provider of microscopy solutions for a variety of ... These special web promotions are now being extended through to August ... stereomicroscopy instrument and a 5 percent discount for conversion of certain ...
... 2010 Financial Results , , , ... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) will host a conference call discussing ... Friday, July 30, 2010 at 11:00 AM ET ( 8:00 AM PT ... Dial-in information for the earnings call on July ...
Cached Biology Technology:Depth charge: Using atomic force microscopy to study subsurface structures 2Carl Zeiss Offers Online Promotions – Discounts on Stereomicroscopy and Converting to 3D Imaging 2Carl Zeiss Offers Online Promotions – Discounts on Stereomicroscopy and Converting to 3D Imaging 3Angiotech Pharmaceuticals Announces Conference Call and Webcast 2
(Date:10/29/2014)... the Society of Interventional Radiology,s (SIR) 40th ... one place where interventional radiologists, diagnostic radiologists, ... can come together to find the most ... discussed and tested. , "Connecting a ... SIR 2015 will feature essential updates on ...
(Date:10/29/2014)... Plants rely on sunlight to make their food, but they ... do. Recently, scientists discovered a group of molecules in plants ... in the Journal of the American Chemical Society , ... plant sunscreens work. , Timothy Zwier and colleagues at Purdue ... to daily can cause serious damage to plant DNA and, ...
(Date:10/29/2014)... nanoparticles is all the rage. Thousands of scientists worldwide ... of whether titanium dioxide nanoparticles from sun creams can ... carbon nanotubes from electronic products are as hazardous for ... nanoparticles in food can get into the blood via ... research funds are flowing – and the number of ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3
... The Patagonian Hippidion horse genus and North American stilt-legged ... tree, according to a new article in the open ... Alan Cooper, and colleagues use ancient DNA to argue ... and that American stilt-legged horses were American endemics, not ...
... of Toronto have mapped the molecular details that show ... immortalizes cells and causes them to continuously grow, thereby ... virus (EBV) is one of the most common human ... certain b-cell cancers like Burkitt's lymphoma as well as ...
... there's a recent wiki article with more details . New ... rat? A Guinea pig? Try none of the above. , A ... rodent with stubby legs and a tail covered in dense hair. ... actually more like a guinea pig or chinchilla. But not quite. ...
Cached Biology News:Ancient DNA helps clarify the origins of two extinct New World horse species 2U of T researchers map role of Epstein-Barr virus in cancer 2Scientists discover odd-ball rodent 2
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
Goat polyclonal to HA1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: TLGSCRERQPEFV from the C terminus of human HA1. Entrez GeneID: 23526 Swiss Protein ID: O78181...
ATP-binding cassette sub-family D member 4 (Peroxisomal membrane protein 69) (PMP69) (Peroxisomal membrane protein 1-like) (PXMP1-L) (P70R). [Source:Uniprot/SWISSPROT;Acc:O14678] Antigen: Recombi...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Biology Products: